Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Time to progression after first ipilimumab treatment</td><td class="align_center">Number of cases (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">&lt;6 months</td><td class="align_center">3 (14)</td></tr><tr><td class="align_left">6–12 months</td><td class="align_center">15 (68)</td></tr><tr><td class="align_left">&gt;12 months</td><td class="align_center">4 (18)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>PFS between challenge and rechallenge.</div>

Journal of Skin Cancer

tab3

Table 3

Table 3: Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma 